Aneta Cymbaluk-PÅ,oska

List of Publications by Year
in descending order

46 papers	466 citations	758635 12 h-index	839053 18 g-index
46 all docs	46 docs citations	46 times ranked	618 citing authors

#	Article	IF	Citations
1	Clinical Relevance of Soluble Forms of Immune Checkpoint Molecules sPD-1, sPD-L1, and sCTLA-4 in the Diagnosis and Prognosis of Ovarian Cancer. Diagnostics, 2022, 12, 189.	1.3	4
2	Clinical Significance of BTLA, CD27, CD70, CD28 and CD80 as Diagnostic and Prognostic Markers in Ovarian Cancer. Diagnostics, 2022, 12, 251.	1.3	6
3	Effectiveness of Different Algorithms and Cut-off Value in Preeclampsia First Trimester Screening. Journal of Pregnancy, 2022, 2022, 1-11.	1.1	2
4	Complementary Methods in Cancer Treatment—Cure or Curse?. International Journal of Environmental Research and Public Health, 2021, 18, 356.	1.2	6
5	The Influence of Biologically Active Substances Secreted by the Adipose Tissue on Endometrial Cancer. Diagnostics, 2021, 11, 494.	1.3	14
6	Approaches to the Diagnosis and Management of Ovarian Cancer in Pregnancy. Cancer Management and Research, 2021, Volume 13, 2329-2339.	0.9	6
7	Long-Term Follow-Up of a Female Patient Treated with Olaparib—Hope for a Long Life without Relapse?. International Journal of Environmental Research and Public Health, 2021, 18, 3430.	1.2	1
8	Can the Determination of HE4 and CA125 Markers Affect the Treatment of Patients with Endometrial Cancer?. Diagnostics, 2021, 11, 626.	1.3	11
9	Molecular Pathways of Cellular Senescence and Placental Aging in Late Fetal Growth Restriction and Stillbirth. International Journal of Molecular Sciences, 2021, 22, 4186.	1.8	16
10	Importance of Potential New Biomarkers in Patient with Serouse Ovarian Cancer. Diagnostics, 2021, 11, 1026.	1.3	2
11	Application of Telehealth in Prenatal Care during the COVID-19 Pandemic—A Cross-Sectional Survey of Polish Women. Journal of Clinical Medicine, 2021, 10, 2570.	1.0	11
12	Therapeutic Management of Rare Primary Ovarian Neoplasms: Carcinosarcoma, Leiomyosarcoma, Melanoma and Carcinoid. International Journal of Environmental Research and Public Health, 2021, 18, 7819.	1.2	5
13	Rhabdomyosarcoma of the Cervix in a Post-Menopausal Woman—An Unparalleled Phenomenon. International Journal of Environmental Research and Public Health, 2021, 18, 7851.	1.2	1
14	The Analysis of NADPH Quinone Reductase 1 (NQO1) Polymorphism in Polish Patients with Colorectal Cancer. Biomolecules, 2021, 11, 1024.	1.8	2
15	Diagnosis of placental insufficiency independently of clinical presentations using sFlt-1/PLGF ratio, including SGA patients. Pregnancy Hypertension, 2021, 25, 244-248.	0.6	6
16	Endometriosis—A Multifaceted Problem of a Modern Woman. International Journal of Environmental Research and Public Health, 2021, 18, 8177.	1.2	12
17	The Clinical Importance of IL-6, IL-8, and TNF-α in Patients with Ovarian Carcinoma and Benign Cystic Lesions. Diagnostics, 2021, 11, 1625.	1.3	13
18	Fertility Preservation and Long-Term Monitoring of Gonadotoxicity in Girls, Adolescents and Young Adults Undergoing Cancer Treatment. Cancers, 2021, 13, 202.	1.7	18

#	Article	IF	Citations
19	Metalloproteinases in Endometrial Cancer—Are They Worth Measuring?. International Journal of Molecular Sciences, 2021, 22, 12472.	1.8	3
20	Immunotherapy of Ovarian Cancer with Particular Emphasis on the PD-1/PDL-1 as Target Points. Cancers, 2021, 13, 6063.	1.7	8
21	Herlyn-Werner-Wunderlich Syndrome: Comparison of Two Cases. International Journal of Environmental Research and Public Health, 2020, 17, 7173.	1.2	5
22	Could Galectin 3 Be a Good Prognostic Factor in Endometrial Cancer?. Diagnostics, 2020, 10, 635.	1.3	4
23	The Role of Zinc and Copper in Gynecological Malignancies. Nutrients, 2020, 12, 3732.	1.7	57
24	Sexuality of Women after Gynecological Surgeries. Healthcare (Switzerland), 2020, 8, 393.	1.0	1
25	The Suitability of FGF21 and FGF23 as New Biomarkers in Endometrial Cancer Patients. Diagnostics, 2020, 10, 414.	1.3	15
26	Evaluation of indications for amniocentesis in cases of normal fetal ultrasound results. Ginekologia Polska, 2020, 91, 693-699.	0.3	0
27	The sFlt-1/PlGF ratio values within the <38, 38–85 and >85 brackets as compared to perinatal outcomes. Journal of Perinatal Medicine, 2019, 47, 732-740.	0.6	17
28	The role of lipocalin-2 serum levels in the diagnostics of endometrial cancer. Cancer Biomarkers, 2019, 24, 315-324.	0.8	7
29	Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy. Hereditary Cancer in Clinical Practice, 2019, 17, 10.	0.6	1
30	Double-Emulsion Copolyester Microcapsules for Sustained Intraperitoneal Release of Carboplatin. Journal of Functional Biomaterials, 2019, 10, 55.	1.8	3
31	Expression of selected angiogenesis-related small microRNAs in patients with abnormally increased secretion of glucocorticoids. Endokrynologia Polska, 2019, 70, 489-495.	0.3	5
32	Risk model in women with ovarian cancer without mutations. Open Medicine (Poland), 2018, 13, 565-574.	0.6	0
33	Circulating Serum Level of Visfatin in Patients with Endometrial Cancer. BioMed Research International, 2018, 2018, 1-9.	0.9	24
34	Evaluation of biologically active substances promoting the development of or protecting against endometrial cancer. OncoTargets and Therapy, 2018, Volume 11, 1363-1372.	1.0	27
35	Suitability assessment of baseline concentration of MMP3, TIMP3, HE4 and CA125 in the serum of patients with ovarian cancer. Journal of Ovarian Research, 2018, 11, 1.	1.3	48
36	Could HE4 level measurements during first-line chemotherapy predict response to treatment among ovarian cancer patients?. PLoS ONE, 2018, 13, e0194270.	1.1	14

#	Article	IF	Citations
37	Thrombospondin-I concentrations behavior in plasma of patients with ovarian cancer. Cancer Biomarkers, 2017, 20, 31-39.	0.8	7
38	Clinical Relevance of NGAL/MMP-9 Pathway in Patients with Endometrial Cancer. Disease Markers, 2017, 2017, 1-8.	0.6	21
39	HE4 Serum Levels in Patients with BRCA1 Gene Mutation Undergoing Prophylactic Surgery as well as in Other Benign and Malignant Gynecological Diseases. Disease Markers, 2017, 2017, 1-13.	0.6	7
40	Clinical importance of serum HE4 and MMP2 levels in endometrial cancer patients. OncoTargets and Therapy, 2017, Volume 10, 3169-3175.	1.0	15
41	Ectopic pregnancy treatment by combination therapy. Open Medicine (Poland), 2016, 11, 530-536.	0.6	1
42	Diagnostic usefulness of the Risk of Ovarian Malignancy Algorithm using the electrochemiluminescence immunoassay for HE4 and the chemiluminescence microparticle immunoassay for CA125. Oncology Letters, 2016, 12, 3101-3114.	0.8	13
43	New poly(ester-amide) copolymers modified with polyether (PEAE) for anticancer drug encapsulation. Journal of Microencapsulation, 2016, 33, 702-711.	1.2	2
44	Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers. Journal of Ovarian Research, 2016, 9, 11.	1.3	10
45	Can ROMA algorithm stratify ovarian tumor patients better when being based on specific age ranges instead of the premenopausal and postmenopausal status?. Tumor Biology, 2016, 37, 8879-8887.	0.8	10
46	MMP3 in Comparison to CA 125, HE4 and the ROMA Algorithm in Differentiation of Ovarian Tumors. Asian Pacific Journal of Cancer Prevention, 2016, 17, 2597-603.	0.5	5